Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KEPPRA vs ELEPSIA XR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Levetiracetam binds to synaptic vesicle protein 2A (SV2A), modulating neurotransmitter release and reducing neuronal hyperexcitability. It also inhibits high-voltage N-type calcium channels and reduces GABAergic and glycinergic inhibition.
Levetiracetam, the active component, binds to synaptic vesicle glycoprotein 2A (SV2A), modulating neurotransmitter release and reducing neuronal hyperexcitability. The exact mechanism of antiepileptic effect is unknown.
Adjunctive therapy for partial-onset seizures (FDA),Adjunctive therapy for myoclonic seizures in juvenile myoclonic epilepsy (FDA),Adjunctive therapy for primary generalized tonic-clonic seizures (FDA),Off-label: Bipolar disorder, migraine prophylaxis, neuropathic pain, status epilepticus
Adjunctive therapy for partial-onset seizures in adults and pediatric patients aged 4 years and older with epilepsy,Off-label: status epilepticus, migraine prophylaxis (limited evidence)
500 mg orally twice daily, titrated up to 1500 mg twice daily as tolerated.
ELEPSIA XR (levetiracetam extended-release) 1000 mg orally once daily. May be increased by 1000 mg/day every 2 weeks to a maximum of 3000 mg once daily.
6-8 hours in adults; prolonged to 10-18 hours in renal impairment (Cr Cl <30 m L/min); clinical context: dosing interval adjustment required in renal disease.
Terminal elimination half-life is 14-17 hours; requires dose adjustment in renal impairment.
Levetiracetam is not extensively metabolized; ~66% of the dose is excreted unchanged in urine. Metabolism occurs via enzymatic hydrolysis of the acetamide group, independent of cytochrome P450. Major metabolite is the carboxylic acid derivative (ucb L057), which is pharmacologically inactive.
Partially hydrolyzed by esterases in plasma and tissues; minor metabolism via CYP450 enzymes (CYP3A4, CYP2C9, CYP2C19) to inactive metabolites. Approximately 66% excreted unchanged in urine.
Renal: 66% unchanged; 27% as inactive metabolite; 0.3% fecal.
Primarily renal (70% unchanged, 20% as inactive metabolites); minor fecal (10%).
<10% bound to plasma proteins (albumin).
92-97% bound to serum albumin.
0.5-0.7 L/kg; approximates total body water; clinical meaning: extensive distribution into tissues, including brain.
0.9-1.1 L/kg; indicates moderate extravascular distribution.
Oral: 100% (immediate-release formulation); IV: 100%.
Oral: Approximately 80% with food; may be lower on empty stomach.
Cr Cl 50-80 m L/min: 500-1000 mg every 12 hours; Cr Cl 30-49 m L/min: 250-750 mg every 12 hours; Cr Cl <30 m L/min: 250-500 mg every 12 hours; ESRD on dialysis: 500-1000 mg once daily with 250-500 mg supplemental dose after dialysis.
For creatinine clearance (Cr Cl) 50-80 m L/min: 1000 mg every 24 hours. Cr Cl 30-49 m L/min: 500 mg every 24 hours. Cr Cl <30 m L/min: 250 mg every 24 hours. End-stage renal disease on dialysis: 500 mg every 24 hours with a supplemental dose of 500 mg after dialysis.
No specific adjustment for hepatic impairment; use caution in severe hepatic impairment.
Mild to moderate hepatic impairment (Child-Pugh A or B): No dose adjustment required. Severe hepatic impairment (Child-Pugh C): Reduce dose by 50%; for Cr Cl <60 m L/min, adjust both for renal function and hepatic impairment.
1 month to <6 months: 7 mg/kg twice daily, titrate to 21 mg/kg twice daily; 6 months to <4 years: 10 mg/kg twice daily, titrate to 25 mg/kg twice daily; 4 to <16 years: 10 mg/kg twice daily, titrate to 30 mg/kg twice daily (maximum 3000 mg/day).
ELEPSIA XR is not indicated for pediatric patients. Immediate-release levetiracetam dosing for pediatric epilepsy: 20 mg/kg/day in two divided doses, titrated up to 40-60 mg/kg/day based on response; maximum 3000 mg/day for children ≥12 years.
Start at 250-500 mg twice daily; titrate slowly due to age-related renal function decline.
Elderly patients (>65 years) often have reduced creatinine clearance. Adjust dose based on renal function (see renal_adjustment). Start at lower end of dosing range; monitor for somnolence and dizziness.
None
Not applicable (no FDA boxed warning).
Behavioral and psychiatric symptoms: psychosis, aggression, suicidal ideation,Somnolence and fatigue, dose-dependent,Stevens-Johnson syndrome and toxic epidermal necrolysis (rare),Hematologic abnormalities: decreased red blood cell, white blood cell, and platelet counts,Acute kidney injury (rare), intercurrent illness may increase risk,Avoid abrupt discontinuation to minimize seizure exacerbation or status epilepticus
Psychiatric adverse reactions: including agitation, hostility, aggression, anxiety, and paranoid reactions, which may be severe. Monitor for behavioral changes.,Suicidal ideation and behavior: increased risk of suicidal thoughts or behavior in patients taking antiepileptic drugs. Monitor for emergence or worsening of depression.,Somnolence and dizziness: common, impairing ability to drive or operate machinery.,Withdrawal seizures: abrupt discontinuation may increase seizure frequency. Taper gradually.
Hypersensitivity to levetiracetam or any of its components
Hypersensitivity to levetiracetam or any component of the formulation
No significant food interactions. Levetiracetam absorption is not affected by food. Avoid alcohol as it may increase CNS depression.
Avoid high-fat meals as they may delay absorption. No specific food restrictions, but maintain adequate hydration to prevent nephrolithiasis.
Increased risk of major congenital malformations, particularly neural tube defects (e.g., spina bifida), cleft palate, and cardiovascular defects, especially with first trimester exposure. Risk is dose-dependent and higher with polytherapy. Second and third trimester exposure may be associated with neurodevelopmental impairments.
First trimester: Increased risk of major congenital malformations including neural tube defects, cleft palate, and cardiac defects due to folate antagonism. Second and third trimesters: Risk of intrauterine growth restriction, preterm birth, and neonatal hemorrhage. Third trimester: Potential for kernicterus and transient neonatal hemolytic anemia. Antiepileptic Drug (AED) use in pregnancy overall associated with developmental delay and autism spectrum disorder.
Levetiracetam is excreted into breast milk with an M/P ratio of approximately 1.0. Infant serum levels are about 10-30% of maternal levels. Generally considered compatible with breastfeeding, but monitor infant for drowsiness, poor feeding, and developmental milestones.
Excreted into breast milk; M/P ratio approximately 0.2-0.4. American Academy of Pediatrics recommends caution due to potential for hepatotoxicity and hemolytic anemia in the neonate. Avoid breastfeeding if alternative agents available.
Pregnancy increases levetiracetam clearance by 30-60%, especially in the second and third trimesters. Monitor serum trough concentrations every 1-2 months and increase dose as needed to maintain therapeutic levels. Postpartum, reduce dose to pre-pregnancy levels within the first week.
Serum levels decline by 50-70% in pregnancy due to increased volume of distribution and hepatic metabolism; total daily dose may need to be increased by 30-50% in second and third trimesters. Monitor free drug concentrations and adjust to maintain therapeutic range. Reduce dose postpartum to pre-pregnancy levels gradually over 1-2 weeks.
Levetiracetam (Keppra) is a broad-spectrum AED with minimal drug interactions. Dosing must be adjusted for renal function (Cr Cl <80 m L/min). Monitor for behavioral changes, especially in pediatric patients. IV formulation can be administered without ECG monitoring. No need for therapeutic drug monitoring; efficacy and tolerability guide dosing.
ELEPSIA XR (topiramate extended-release) is indicated for epilepsy and migraine prophylaxis. Titrate slowly to minimize cognitive side effects. Monitor for metabolic acidosis, especially in patients with predisposing conditions. Contraindicated in pregnancy due to risk of oral clefts. Adjust dose in renal impairment (Cr Cl <70 m L/min).
Take exactly as prescribed; do not stop suddenly as withdrawal seizures may occur.,Report any unusual mood changes, depression, or aggressive behavior to your doctor.,May cause dizziness or drowsiness; avoid driving until effects are known.,Take with or without food; do not crush extended-release tablets.,Drink plenty of fluids to prevent kidney stones, though not a common side effect.
Swallow capsules whole; do not crush or chew.,Take with or without food; avoid high-fat meals which may delay absorption.,May cause dizziness, drowsiness, or blurred vision; avoid driving until effects known.,Drink plenty of fluids to reduce risk of kidney stones.,Stop taking and contact doctor if you experience eye pain, vision changes, or fever.,Use effective contraception during treatment; inform doctor if pregnant or planning pregnancy.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KEPPRA vs ELEPSIA XR, answered by our medical review team.
KEPPRA is a Antiepileptic that works by Levetiracetam binds to synaptic vesicle protein 2A (SV2A), modulating neurotransmitter release and reducing neuronal hyperexcitability. It also inhibits high-voltage N-type calcium channels and reduces GABAergic and glycinergic inhibition.. ELEPSIA XR is a Antiepileptic that works by Levetiracetam, the active component, binds to synaptic vesicle glycoprotein 2A (SV2A), modulating neurotransmitter release and reducing neuronal hyperexcitability. The exact mechanism of antiepileptic effect is unknown.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KEPPRA and ELEPSIA XR depend on the specific clinical indication. These are both Antiepileptic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KEPPRA is: 500 mg orally twice daily, titrated up to 1500 mg twice daily as tolerated.. The standard adult dose of ELEPSIA XR is: ELEPSIA XR (levetiracetam extended-release) 1000 mg orally once daily. May be increased by 1000 mg/day every 2 weeks to a maximum of 3000 mg once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between KEPPRA and ELEPSIA XR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. KEPPRA is classified as Category C. Increased risk of major congenital malformations, particularly neural tube defects (e.g., spina bifida), cleft palate, and cardiovascular defects, especially with first trimester e. ELEPSIA XR is classified as Category C. First trimester: Increased risk of major congenital malformations including neural tube defects, cleft palate, and cardiac defects due to folate antagonism. Second and third trimes. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.